Metronomic Oral Topotecan with Pazopanib Is an Active Antiangiogenic Regimen in Mouse Models of Aggressive Pediatric Solid Tumor

Página do item simplificado
dc.contributor.authorKumar, Sushil
dc.contributor.authorMokhtari, Reza Bayat
dc.contributor.authorSheikh, Reihaneh
dc.contributor.authorWu, Bing
dc.contributor.authorZhang, Libo
dc.contributor.authorXu, Ping
dc.contributor.authorMan, Shan
dc.contributor.authorOliveira, Indhira Dias [UNIFESP]
dc.contributor.authorYeger, Herman
dc.contributor.authorKerbel, Robert S.
dc.contributor.authorBaruchel, Sylvain
dc.contributor.institutionHosp Sick Children
dc.contributor.institutionUniv Toronto
dc.contributor.institutionSunnybrook Hlth Sci Ctr
dc.contributor.institutionUniversidade Federal de São Paulo (UNIFESP)
dc.date.accessioned2016-01-24T14:17:08Z
dc.date.available2016-01-24T14:17:08Z
dc.date.issued2011-09-01
dc.description.abstractPurpose: Low dose metronomic (LDM) chemotherapy, combined with VEGF signaling pathway inhibitors, is a highly effective strategy to coordinately inhibit angiogenesis and tumor growth in many adult preclinical cancer models. We have tested the efficacies of daily oral LDM topotecan alone and in combination with pazopanib, a VEGF receptor inhibitor, in three pediatric extracranial solid tumor mouse models.Experimental Design: in vitro dose-response study of topotecan and pazopanib was conducted on several neuroblastoma, osteosarcoma, and rhabdomyosarcoma cell lines. in vivo antitumor efficacies of the LDM topotecan and pazopanib as single agents and in combination were tested on 4 subcutaneous xenograft models and on 2 neuroblastoma metastatic models. Circulating angiogenic factors such as circulating endothelial cells (CEC), circulating endothelial progenitor cells (CEP), and microvessel densities were used as surrogate biomarker markers of antiangiogenic activity.Results: in vitro, topotecan caused a dose-dependent decrease in viabilities of all cell lines, while pazopanib did not. in vivo, combination of topotecan + pazopanib (TP + PZ) showed significant antitumor activity and significant enhancement in survival compared with the respective single agents in all models. Reductions in viable CEP and/or CEC levels and tumor microvessel density were correlated with tumor response and therefore confirmed the antiangiogenic activity of the regimens. Pharmacokinetic studies of both drugs did not reveal any drug-drug interaction.Conclusion: Metronomic administration of TP + PZ showed a statistically significant antitumor activity compared with respective single agents in pediatric tumor mouse models and represent a valid option as a maintenance therapy in aggressive pediatric solid tumors. Clin Cancer Res; 17(17); 5656-67. (C)2011 AACR.en
dc.description.affiliationHosp Sick Children, New Agent & Innovat Therapy Program, Div Hematol & Oncol, Dept Pediat, Toronto, ON M5G 1X8, Canada
dc.description.affiliationHosp Sick Children, Dept Pediat Lab Med, Toronto, ON M5G 1X8, Canada
dc.description.affiliationUniv Toronto, Inst Med Sci, Toronto, ON M5S 1A1, Canada
dc.description.affiliationSunnybrook Hlth Sci Ctr, Toronto, ON M4N 3M5, Canada
dc.description.affiliationUniversidade Federal de São Paulo, Pediat Oncol Inst GRAACC, Dept Pediat, São Paulo, Brazil
dc.description.affiliationUnifespUniversidade Federal de São Paulo, Pediat Oncol Inst GRAACC, Dept Pediat, São Paulo, Brazil
dc.description.sourceWeb of Science
dc.description.sponsorshipCanadian Foundation for Innovation (CFI)
dc.description.sponsorshipJames Birrell Neuroblastoma Fund
dc.description.sponsorshipGlaxoSmithKline, Collegeville, PA
dc.description.sponsorshipSickkids Foundation, Toronto
dc.description.sponsorshipUniversity of Toronto (Institute of Medical Sciences)
dc.format.extent5656-5667
dc.identifierhttp://dx.doi.org/10.1158/1078-0432.CCR-11-0078
dc.identifier.citationClinical Cancer Research. Philadelphia: Amer Assoc Cancer Research, v. 17, n. 17, p. 5656-5667, 2011.
dc.identifier.doi10.1158/1078-0432.CCR-11-0078
dc.identifier.issn1078-0432
dc.identifier.urihttp://repositorio.unifesp.br/handle/11600/33988
dc.identifier.wosWOS:000294477600016
dc.language.isoeng
dc.publisherAmer Assoc Cancer Research
dc.relation.ispartofClinical Cancer Research
dc.rightsinfo:eu-repo/semantics/openAccess
dc.titleMetronomic Oral Topotecan with Pazopanib Is an Active Antiangiogenic Regimen in Mouse Models of Aggressive Pediatric Solid Tumoren
dc.typeinfo:eu-repo/semantics/article
Arquivos
Coleções
Em verificação - Geral